Results 21 to 30 of about 9,787 (247)

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. [PDF]

JCI Insight, 2018
The presence of a reservoir of latently infected cells in HIV-infected patients is a major barrier towards finding a cure. One active cure strategy is to find latency-reversing agents that induce viral reactivation, thus leading to immune cell recognition and elimination of latently infected cells, known as the shock-and-kill strategy.
Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.   +10 more
europepmc   +4 more sources

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA. [PDF]

Biol Open, 2020
Infection of HIV-1 remains incurable because long-lived, latently-infected cells persist during prolonged antiretroviral therapy. Attempts to pharmacologically reactivate and purge the latent reservoir with latency reactivating agents (LRAs) such as protein kinase C (PKC) agonists (e.g. ingenol A) or histone deacetylase (HDAC) inhibitors (e.g.
Taylor JP, Armitage LH, Aldridge DL, Cash MN, Wallet MA.   +4 more
europepmc   +5 more sources

Novel Latency Reversal Agents for HIV-1 Cure. [PDF]

Annu Rev Med, 2018
Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate ...
Spivak AM, Planelles V.
europepmc   +4 more sources

Ethnopharmacological exploration and isolation of HIV-1 latency-reversing agents from Sudanese medicinal plants [PDF]

Frontiers in Pharmacology
HIV-1 infection remains a major health challenge, especially in resource-limited settings such as Sudan, where traditional medicine is widely practiced for managing infectious diseases, including HIV/AIDS.
Khaled M. Elamin, Naoki Kishimoto, Naoki Kishimoto, Teppei Kawahara, Sara Mustafa Idris Elbashir, Tae Yasutake, Mikiyo Wada, Yuki Hitora, Maha Kordofani, Wadah Osman, Wadah Osman, Mustafa Idris Elbashir, Shogo Misumi, Shogo Misumi   +13 more
doaj   +2 more sources

T cell toxicity of HIV latency reversing agents

Pharmacological Research, 2019
Combination antiretroviral therapy reduces morbidity and mortality in HIV infected patients. However, the cure of HIV infection is hindered by the persistence of the latent HIV reservoir. Latency reversing agents (LRAs) are developed to target the HIV latently infected cells for HIV reactivation.
Manzhi Zhao, Elisa De Crignis, Casper Rokx   +2 more
exaly   +3 more sources

Approaches to discover latency-reversing agents

Journal of Virus Eradication, 2015
doaj   +2 more sources

Identification of a promising new class of latency reversing agents

Journal of Virus Eradication, 2017
A. Gramatica, W. Greene, R. Schwarzer, M. Montano, T. Packard, E. Herzig, Warner Greene   +6 more
doaj   +2 more sources

Optimisation of Smac mimetics as HIV-1 latency reversing agents

Journal of Virus Eradication, 2019
L. Pache, P. Teriete, M.D. Marsden, A.M. Spivak, D. Heimann, A.J. Portillo, V. Planelles, J.A. Zack, N.D.P. Cosford, S.K. Chanda   +9 more
doaj   +2 more sources

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal

Journal of Virus Eradication, 2016
T.M. Mota, G. Khoury, J.C. Jacobson, H.K. Lu, F. Wightman, d.e.r. Sluis, J.L. Anderson, P.U. Cameron, S.R. Lewin, D.F.J. Purcell, R.M. Van   +10 more
doaj   +2 more sources

Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens [PDF]

Medicinal Research Reviews, 2020
Pargol Hashemi, Ivan Sadowski
exaly   +2 more sources